NEW YORK (GenomeWeb News) – Arno Therapeutics today announced it has inked an exclusive, worldwide licensing deal with the University of Minnesota for a technology covering a gene expression signature derived from archived breast cancer tissue samples.

As part of the deal, Arno will continue development of a progesterone receptor gene signature as a potential companion diagnostic for anti-progestins, including Arno's lead compound called onapristone for treating men's and women's cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.